Phase 3 EMT2 trial demonstrates survival benefit for high-dose EPA
Patients assigned to receive high-dose eicosapentaenoic acid (EPA), an omega-3 fatty acid, before and after surgery for colorectal cancer liver metastases had longer overall survival than those assigned to receive placebo, according to results of the phase 3 EMT2 trial presented at the ESMO Congress 2026.
Read original article on The Medical News →Related news
-
One in three young adults turns to AI for substance use
United Kingdom
-
Geriatric chronic kidney disease patients benefit from SGLT2 inhibition
United Kingdom
-
Airborne ESKAPE bacteria pose severe risks to immunocompromised patients
United Kingdom
-
Next generation KRAS inhibitor divarasib significantly extends lung cancer survival
United Kingdom
-
Substance use driving increases in emergency department visits, hospitalizations for young mothers
United Kingdom
-
A simple liquid can stop cavities without drilling, major study confirms
United States
-
Can happy feelings trigger eating too? Researchers explored both sides of emotional eating
United Kingdom
-
Beer, wine or spirits: A large study finds different mortality patterns for each
United Kingdom